Greenwich Rx Recalls Compounded Sterile Products Nationwide
Greenwich Rx recalls compounded sterile products nationwide after an FDA inspection identified potential sterility assurance failures across lots still within beyond-use dates.


A post-inspection recall from Greenwich Rx, a 503A compounding pharmacy based in Tomball, Texas, puts sterility assurance controls back under the microscope for QA directors and regulatory leads managing compounded sterile product programs. The voluntary nationwide recall, announced November 20, 2026, covers specific lots of compounded sterile products still within their beyond-use dates, a detail that sharpens the compliance exposure, since affected units were actively in circulation at the time of action.
The recall was triggered by a U.S. Food and Drug Administration inspection followed by Greenwich Rx's own product evaluation, which identified a potential lack of sterility assurance. No confirmed contamination has been identified, and no adverse events have been reported to date; the action is precautionary. Even so, the risk statement is unambiguous: a sterile drug product that fails sterility assurance carries the potential for serious, life-threatening infection in patients.
The scope extends beyond Greenwich Rx's direct customer base. Some affected lots were compounded by Greenwich Rx on behalf of Clove Rx, a separate pharmacy, meaning patients and clinics that received product through Clove Rx are also subject to the recall, whether or not they have received direct notification by mail. Affected products were dispensed nationwide between August 10 and September 21, 2026. Customers are directed to cross-reference their medication labels against the full lot list published at greenwichrx.org/news/general-recall-2026-11.
For QA leads at 503A operations, the compliance read centers on two intersecting obligations: the adequacy of sterility validation data supporting beyond-use date assignments, and the robustness of CAPA documentation generated in response to inspection observations. Under 21 CFR Part 211 and USP standards applicable to compounded sterile preparations, sterility assurance is not a post-market inference, it is a pre-release requirement. A recall initiated while products remain within assigned beyond-use dates signals that the original sterility assurance basis may not have been adequately established or documented.
Recall coordination is being handled through Sedgwick, reachable at 888-243-5547 or [email protected]. Adverse events and quality complaints may be submitted to FDA's MedWatch program.
The FDA's inspection findings underlying this action have not been publicly detailed, but the agency's involvement in a precautionary recall of in-date sterile compounded products will likely inform how investigators approach sterility assurance documentation at 503A facilities in upcoming inspection cycles.
Source: FDA MedWatch Safety Alerts via FDA.gov, November 20, 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
India Positions Itself as Global Diabetes R&D Hub Targeting GLP-1 and Microbiome Therapies

Capricor Therapeutics Receives FDA Complete Response Letter for Deramiocel

Discussion